Tissue damage following cardiac arrest or other cardiovascular events is an ongoing problem with great unmet need. DecImmune Therapeutics Inc. is a new biotechnology company focused on developing peptide and antibody therapeutics for acute inflammation and tissue damage following vascular injury by way of the N2-IgM pathway.